Life Science Insights 360 Podcasts

We are honored to welcome Dr. Ron Cohen, CEO of Oryon Cell Therapies and a distinguished leader in the biotechnology industry.With more than three decades of experience building innovative biotech companies, raising significant capital, and advancing therapies for patients, Dr. Cohen has made a lasting impact on the life sciences community.At Oryon Cell Therapies, he is leading the development of next-generation cell therapies with a focus on neurodegenerative diseases and the potential of regenerative medicine to address some of the most challenging conditions in healthcare.In this conversation, we explore his entrepreneurial journey, leadership lessons, biotech financing, the rapidly evolving field of cell therapy, and his vision for the future of regenerative medicine.Key Topics Discussed#Dr. Ron Cohen’s three-decade journey in biotechnology and entrepreneurship#What inspired him to pursue biotech rather than a traditional medical career#Lessons learned from setbacks and challenges throughout his entrepreneurial journey#His leadership philosophy and how it has evolved over the past 30 years#Why he joined Oryon Cell Therapies and his vision for its next chapter#The evolution of cell therapy and regenerative medicine#Scientific opportunities that were not possible just five years ago#What differentiates Oryon Cell Therapies in the regenerative medicine landscape#The potential of cell therapy in treating neurodegenerative diseases#Therapeutic areas where cell therapy could deliver major breakthroughs#Raising more than $1.1 billion in capital throughout his career#Advice for first-time biotech founders seeking investment#What investors look for in successful biotech CEOs beyond great science#Building resilient organizations and high-performance biotech teams#Creating a culture that thrives through both successes and setbacksEpisode Highlights#The Future of Cell Therapy — Exploring how advances in cell biology and regenerative medicine are opening new possibilities for treating complex diseases.#Neurodegenerative Diseases — Understanding the potential of next-generation cell therapies to address some of the most challenging neurological conditions.#Biotech Entrepreneurship — Dr. Cohen shares lessons from more than 30 years of building companies and advancing innovative therapies.#Raising Capital — Insights into biotech fundraising, investor expectations, and what founders need to demonstrate beyond compelling science.#Leadership & Culture — Practical lessons on building teams, navigating setbacks, and creating organizations capable of sustained innovation.#The Future of Biotechnology — Dr. Cohen shares his perspective on where cell therapy and regenerative medicine are heading and the opportunities that lie ahead.Whether you’re a biotech entrepreneur, scientist, physician, investor, pharmaceutical executive, cell therapy researcher, or healthcare innovator, this episode provides valuable perspectives on the science, business, and leadership shaping the next generation of biotechnology.Subscribe for conversations with leaders across biotechnology, pharmaceuticals, healthcare, clinical research, AI, cell therapy, and life sciences.#LifeScienceInsights360 #RonCohen #OryonCellTherapies #CellTherapy #Biotechnology #RegenerativeMedicine #NeurodegenerativeDiseases #Biotech #DrugDevelopment #LifeSciences #HealthcareInnovation #BiotechEntrepreneur #BiotechLeadership #VentureCapital #ClinicalResearch

Dr. Shneider is pioneering innovative approaches to cancer treatment through Elenagen, a novel biological therapeutic being investigated for difficult-to-treat cancers. His unique approach connects human and veterinary oncology, advancing the One Health vision while challenging conventional approaches to biotechnology development.In this conversation, we explore Dr. Shneider’s journey in biotechnology and oncology, the science behind Elenagen, clinical development, cancer immunology, and the potential of combining human and veterinary research to accelerate therapeutic innovation.Key Topics Discussed#Dr. Alexander Shneider’s journey into biotechnology and oncology#The mission and vision behind CureLab Oncology#Understanding Elenagen and its novel approach to cancer treatment#How Elenagen interacts with the immune system#The role of chronic inflammation in cancer#Clinical development and research in difficult-to-treat cancers#Insights into platinum-resistant ovarian cancer#Combining innovative therapies with chemotherapy and immunotherapy#The philosophy of going “from the drug to the mechanism”#Challenging traditional biotechnology development models#The One Health connection between human and veterinary oncology#Cancer research in dogs and its potential relevance to human medicine#How veterinary medicine can contribute to human drug development#Capital-efficient biotech development and innovation#Leadership lessons from building CureLab#The future of cancer treatment, biotechnology, and precision medicineEpisode Highlights#A deep dive into the science and potential of Elenagen#Dr. Shneider’s perspective on the relationship between cancer, inflammation, and immunity#How human and veterinary oncology can work together under the One Health approach#Insights into innovative and capital-efficient biotech development#Perspectives on the future of cancer therapeutics and biotechnology innovation#Leadership and entrepreneurship lessons from a scientist building companies around novel cancer therapiesWhether you're a biotechnology professional, oncologist, researcher, physician, investor, entrepreneur, or healthcare innovator, this episode offers valuable insights into the science, strategy, and innovation shaping the future of cancer treatment.#LifeScienceInsights360 #AlexanderShneider #CureLabOncology #Elenagen #Oncology #CancerResearch #CancerTreatment #Biotechnology #PrecisionMedicine #OneHealth #VeterinaryOncology #DrugDevelopment #Pharma #LifeSciences #HealthcareInnovation

With more than two decades of experience across organizations including West Pharmaceutical Services and Catalent, Elizabeth brings deep expertise in transforming scientific innovation into scalable solutions that help biopharma companies accelerate drug development and bring innovative therapies to patients.Our conversation explores the evolution of the CDMO industry, AustinPx’s innovative KinetiSol® technology, formulation and bioavailability challenges, and the future of pharmaceutical manufacturing and drug delivery.Elizabeth also shares her perspective on how AI, data-driven decision-making, predictive analytics, machine learning, and digital technologies are transforming drug development and manufacturing. We discuss personalized medicine, emerging drug delivery technologies, building high-performing teams, and the leadership principles required to successfully scale a science-driven organization.Drawing from her extensive industry experience, Elizabeth offers valuable insights into how pharmaceutical companies and their development partners can accelerate innovation, overcome complex formulation challenges, and prepare for the future of medicine.Key Topics Discussed#Elizabeth Hickman’s career journey from West Pharmaceutical Services and Catalent to AustinPx#Leadership lessons from more than 20 years in the CDMO industryAustinPx’s innovative approach to pharmaceutical development#What differentiates AustinPx from traditional CDMOsKinetiSol® technology and how it is transforming pharmaceutical formulation#How KinetiSol can help improve bioavailability and address challenging drug candidates#Reducing drug development timelines and manufacturing complexity#Drug formulation challenges facing pharmaceutical and biotech companies#How CDMOs are evolving into strategic innovation partners#Differences between the needs of emerging biotech companies and large pharmaceutical organizations#The growing role of AI, machine learning, predictive analytics, and data-driven decision-making#The potential of digital twins in pharmaceutical manufacturing#Balancing scientific innovation with business growth#Building high-performing, client-focused teams#The impact of personalized medicine on pharmaceutical manufacturing#Emerging drug delivery technologies that could shape the next decade#The future of the global CDMO industryEpisode Highlights#Pharmaceutical Innovation — Elizabeth shares her perspective on turning scientific breakthroughs into scalable pharmaceutical solutions.#KinetiSol® Technology — A closer look at AustinPx’s innovative technology platform and its potential to overcome challenging formulation and bioavailability issues.#The Evolution of CDMOs — How CDMOs are moving beyond traditional manufacturing services to become strategic partners throughout the drug development journey.#AI & Digital Transformation — Exploring how artificial intelligence, predictive analytics, machine learning, and data are changing formulation development and manufacturing.#Future of Drug Delivery — Insights into personalized medicine, emerging delivery technologies, and the changing needs of next-generation therapies.#Leadership & Growth — Elizabeth shares lessons on building strong teams, creating a client-centric culture, and leading through a rapidly changing pharmaceutical landscape.#Industry Outlook — Where Elizabeth sees pharmaceutical manufacturing and the CDMO industry heading over the next five to ten years.#LifeScienceInsights360 #ElizabethHickman #AustinPx #PharmaceuticalDevelopment #DrugDevelopment #DrugDelivery #CDMO #PharmaInnovation #KinetiSol #PharmaceuticalManufacturing #Biotechnology #AIinPharma #DigitalTransformation #PersonalizedMedicine #LifeSciences #HealthcareInnovation #Pharma #Biotech

In this episode of Life Science Insights 360, I'm delighted to welcome Ivanna Rosendal, Vice President of Business Digitalization, a global leader driving digital transformation across clinical development, pharmacovigilance, commercial, and medical organizations.Beyond her executive leadership role, Ivanna is also an author, podcast host, and stand-up comedian, bringing a unique perspective on innovation, leadership, organizational change, and the human side of digital transformation. Drawing from her extensive experience, she shares how life sciences organizations can successfully navigate technological disruption while keeping people, patients, and purpose at the center of innovation.Our conversation explores the future of AI-powered drug development, digital transformation, decentralized clinical trials, leadership in highly regulated industries, and how emerging technologies are reshaping the future of healthcare.## Key Topics Discussed- Ivanna Rosendal's career journey and leadership in business digitalization.- Driving enterprise-wide digital transformation across clinical development, pharmacovigilance, commercial, and medical organizations.- The biggest leadership challenges in implementing digital transformation within highly regulated life sciences companies.- How artificial intelligence is transforming clinical development and accelerating innovation.- The importance of data quality, interoperability, and connected digital ecosystems.- Why digital transformation initiatives succeed—or fail—and lessons for organizational change.- The future of decentralized and hybrid clinical trials.- Leveraging real-world data and real-world evidence to improve clinical decision-making.- Emerging technologies including AI agents, predictive analytics, digital twins, and intelligent automation.- Building cultures that embrace innovation, continuous learning, and change.- Leadership lessons for developing the next generation of life sciences professionals.- Balancing executive leadership with writing, podcasting, and stand-up comedy, and how storytelling and humor strengthen communication and leadership.## Episode Highlights- Expert insights into digital transformation across the life sciences industry.- A forward-looking discussion on AI, data strategy, and the future of clinical development.- Practical leadership advice for driving organizational change and innovation.- Perspectives on emerging technologies that are reshaping drug development and healthcare.- An inspiring conversation about leadership, creativity, communication, and the value of bringing authenticity and humor into the workplace.Whether you're a life sciences executive, digital transformation leader, clinical research professional, healthcare innovator, technology enthusiast, or aspiring leader, this episode offers valuable insights into the strategies, technologies, and leadership principles shaping the future of life sciences.

In this episode of the Life Science Insights Podcast , I'm delighted to welcome Dr. Faisal Mehmud, Chief Medical Officer of Medicus Pharma , a clinical-stage biotechnology company focused on developing innovative therapies for oncology and other high unmet medical needs.With an exceptional career spanning global pharmaceutical leaders including Sanofi, Novartis, Bristol Myers Squibb, Pfizer, and GSK , Dr. Mehmud shares his journey through clinical development, medical leadership, and drug innovation. We explore how Medicus Pharma is advancing novel therapeutic approaches for skin cancer and prostate cancer, and discuss the future of precision oncology, artificial intelligence, and patient-centered drug development.Our conversation highlights the company's lead programs, SkinJect and Teverelix , along with broader industry trends that are transforming clinical research, oncology, and the development of next-generation therapies.## Key Topics Discussed- Dr. Faisal Mehmud's career journey and leadership across global pharmaceutical companies.- Medicus Pharma's mission and its approach to developing innovative oncology therapies.- The science behind SkinJect , a dissolvable microneedle patch designed for localized treatment of skin cancer.- The advantages of localized drug delivery compared with traditional systemic chemotherapy.- Key insights from the Phase 2 clinical study of SkinJect.- An overview of Teverelix and its potential role in treating prostate cancer.- The importance of cardiovascular safety in oncology drug development.- Emerging trends improving the efficiency of clinical trials.- How artificial intelligence and digital technologies are transforming clinical development.- Medicus Pharma's partnership strategy and the value of advancing programs through Phase 2 before strategic collaborations.- The evolution of precision oncology and innovation across the pharmaceutical industry.- Leadership insights, career advice for the next generation of physicians and scientists, and the future outlook for biotechnology innovation.## Episode Highlights- Expert insights into the future of precision oncology and innovative cancer therapeutics.- A deep dive into SkinJect and Teverelix, two promising programs addressing significant unmet medical needs.- Perspectives on AI, digital transformation, and the future of clinical development.- Leadership lessons from decades of experience across some of the world's leading pharmaceutical companies.- A forward-looking discussion on biotechnology innovation, strategic partnerships, and improving outcomes for cancer patients.Whether you're a biotechnology professional, oncologist, clinical researcher, life sciences executive, investor, or healthcare innovator, this episode offers valuable insights into the technologies, strategies, and scientific advances shaping the future of cancer care and precision medicine.

In this episode of the Life Science Insights Podcast, I'm delighted to welcome Dr. John Craighead, CEO of Syntax Bio, a synthetic biology company advancing the next generation of programmable stem cell therapies.With more than 20 years of leadership experience across biotechnology, corporate strategy, and life sciences, Dr. Craighead has held executive leadership roles at organizations including GRAIL, Sanofi, Atara Biotherapeutics, HALO Precision Diagnostics, and now Syntax Bio. He shares his journey from cell biology research to leading innovative biotechnology companies and discusses how scientific innovation, strategic partnerships, and advanced manufacturing are shaping the future of regenerative medicine.Our conversation explores Syntax Bio's mission to engineer programmable stem cell therapies, the challenges of scaling cell-based therapeutics, and the role of synthetic biology, computational biology, and artificial intelligence in accelerating the next generation of precision medicine. We also discuss the company's strategic collaboration with Applied StemCell, biotechnology funding, and the future of programmable cell engineering.## Key Topics Discussed* Dr. John Craighead's career journey from cell biology research to biotechnology leadership.* Leadership lessons from GRAIL, Sanofi, Atara Biotherapeutics, and Syntax Bio.* Syntax Bio's mission to develop programmable stem cell therapies.* The scientific and manufacturing challenges of stem-cell-based therapeutics.* Improving the speed, consistency, and scalability of therapeutic cell manufacturing.* The strategic collaboration between Syntax Bio and Applied StemCell and its impact on innovation.* The growing role of synthetic biology in advancing regenerative medicine.* How computational biology and artificial intelligence are accelerating therapeutic discovery and development.* Balancing personalized therapies with scalable manufacturing.* Building high-performing biotechnology organizations and leading multidisciplinary teams.* The importance of strategic partnerships and investment in advancing biotechnology innovation.* Trends shaping the future of synthetic biology, regenerative medicine, and programmable cell therapies.## Episode Highlights* Insights into the future of programmable stem cell therapies and regenerative medicine.* Expert perspectives on synthetic biology and next-generation therapeutic innovation.* A discussion on manufacturing challenges and scaling advanced cell therapies.* How AI, computational biology, and automation are transforming biotechnology research and development.* Leadership lessons on innovation, strategy, fundraising, and building world-class biotechnology companies.* A forward-looking conversation on the future of precision medicine and engineered cell therapies.Whether you're a biotechnology professional, life sciences executive, researcher, investor, entrepreneur, or student, this episode offers valuable insights into one of the fastest-evolving areas of modern medicine and the technologies that are redefining the future of healthcare.

In this episode of the Life Science Insights Podcast, we sit down with Jimmy Bechtel, Chief Strategy & Site Solutions Officer (CSSO) at the Society for Clinical Research Sites (SCRS), to explore the evolving landscape of clinical research and the critical role research sites play in advancing innovation, improving patient outcomes, and driving more efficient clinical trials.Jimmy shares his perspective on the challenges facing research sites today, the growing importance of site sustainability, and how technology, AI, and stronger collaboration between sponsors, CROs, and research sites are shaping the future of clinical research. We also discuss how patient-centric approaches, operational excellence, and digital transformation are redefining the clinical trial ecosystem.Key Topics DiscussedJimmy Bechtel's professional journey into clinical research and site managementThe meaning of site success in today's clinical trial environmentMajor operational challenges facing clinical research sitesThe growing importance of long-term site sustainabilityStrengthening collaboration between research sites, sponsors, and CROsLeveraging technology to improve site efficiency and reduce administrative burdenThe evolution of decentralized and hybrid clinical trialsStrategies for improving patient engagement and retentionAddressing workforce shortages in clinical researchThe impact of AI and automation on site operationsImproving interoperability and workflow integrationAdvancing diversity, accessibility, and inclusion in clinical trialsBuilding resilient and sustainable research programsEmerging trends shaping the next generation of clinical research sitesEpisode Highlights✔ Expert insights into the challenges and opportunities facing modern clinical research sites✔ Perspectives on AI, digital transformation, and technology-enabled clinical trials✔ Practical strategies for improving site sustainability and operational efficiency✔ A discussion on patient-centric trial design, accessibility, and engagement✔ A forward-looking vision for the future of clinical research and patient careSubscribe to the Life Science Insights Podcast for more conversations with industry leaders, innovators, and experts shaping the future of clinical research, biotechnology, and healthcare.#LifeScienceInsights #ClinicalResearch #ClinicalTrials #SCRS #JimmyBechtel #ResearchSites #SiteManagement #PatientCentricity #DecentralizedTrials #AIInHealthcare #DigitalHealth #Biotechnology #HealthcareInnovation #ClinicalOperations #FutureOfClinicalResearch

In this episode of the Life Science Insights Podcast, we sit down with Mark Van Zee, Founder and CEO of Saku Biosciences, to explore the future of scalable biology and how innovations in cell line development are transforming modern biomanufacturing. Mark shares his journey from bioengineering research to entrepreneurship and explains why the greatest challenge facing biotechnology today is not scientific discovery—but scaling innovation to deliver real-world impact.From breakthrough PicoShell® technology to the future of automation, sustainable biomanufacturing, and next-generation cell engineering, this conversation examines how advanced technology platforms are accelerating drug development, improving manufacturing efficiency, reducing costs, and expanding global access to innovative therapies.Key Topics DiscussedMark Van Zee's journey from bioengineering research to founding Saku BiosciencesWhy biotechnology faces a scalability challenge rather than an R&D challengeUnderstanding PicoShell® technology and its applicationsAccelerating cell line development through advanced screening technologiesThe impact of high-performing producer cells on biomanufacturing efficiencyKey factors biopharma companies consider when evaluating new technology platformsThe role of automation and advanced screening in eliminating development bottlenecksStrengthening biomanufacturing supply chains through modern technologiesSustainable biotechnology and the importance of alternative feedstocksReducing downstream processing costs through improved cell engineeringChallenges and opportunities in scaling biotechnology innovationsBalancing scientific innovation with fundraising and commercializationLessons learned while building Saku BiosciencesThe future of scalable biology across healthcare, food, and industrial biotechnologyEpisode Highlights✔ Why scaling remains one of biotechnology's greatest challenges✔ How PicoShell® technology is transforming cell line development✔ The growing role of automation in modern biomanufacturing✔ Strategies for building more resilient and sustainable biotech supply chains✔ Insights into commercializing breakthrough biotechnology platforms✔ A forward-looking vision for scalable biology and its impact across healthcare and industrySubscribe to the Life Science Insights Podcast for more conversations with innovators, entrepreneurs, and industry leaders shaping the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #SakuBiosciences #Biotechnology #Biomanufacturing #CellLineDevelopment #Bioprocessing #Biopharma #SyntheticBiology #LifeSciences #HealthcareInnovation #Bioengineering #Automation #ScalableBiology #BiotechPodcast #DrugDevelopment

In this episode of the Life Science Insights Podcast, we sit down with Dr. Raviv Pryluk, CEO and Co-Founder of PhaseV, to explore how artificial intelligence and causal machine learning are transforming clinical development. Dr. Pryluk explains how AI-driven trial optimization is making clinical trials faster, smarter, and more efficient—while reducing costs, minimizing risk, and improving the probability of success.We discuss PhaseV's innovative approach to adaptive, causal, and data-driven clinical development, the growing role of AI in clinical decision-making, and how next-generation technologies are helping sponsors design more efficient, personalized, and successful clinical trials.Key Topics DiscussedUnderstanding adaptive, causal, and data-driven clinical developmentHow causal machine learning differs from traditional AI approachesDefining AI-driven clinical trial optimization in practical termsHow PhaseV's Trial Optimizer enhances trial efficiency while reducing costsBalancing statistical rigor with real-world clinical trial constraintsReal-world examples of AI-driven trial optimizationMajor inefficiencies in today's clinical trial ecosystemUsing AI and machine learning to de-risk drug developmentRegulatory perspectives on AI-enabled clinical trial designBuilding trust, transparency, and interpretability in AI-driven decision-makingAddressing data variability and bias across diverse patient populationsLeadership lessons from building and scaling an AI-driven healthcare companyBuilding multidisciplinary teams across AI, biology, and clinical researchThe future of clinical trials: smaller, faster, and more personalized studiesThe long-term impact of AI on the economics of drug developmentEpisode Highlights✔ A clear explanation of causal machine learning and why it matters✔ How AI is optimizing trial design, patient selection, and clinical outcomes✔ Strategies for reducing clinical trial costs, timelines, and development risk✔ The importance of explainable and trustworthy AI in clinical decision-making✔ Leadership insights from building and scaling an AI-first healthcare company✔ A forward-looking vision for the future of AI-powered clinical developmentSubscribe to the Life Science Insights Podcast for more conversations with innovators, researchers, and industry leaders advancing the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #PhaseV #ArtificialIntelligence #ClinicalTrials #DrugDevelopment #MachineLearning #CausalAI #ClinicalResearch #PrecisionMedicine #Biotechnology #HealthcareInnovation #DigitalHealth #LifeSciences #AIInHealthcare #BiotechPodcast

In this episode of the Life Science Insights Podcast, we sit down with Karsten Eastman, CEO and Co-founder of Sethera Therapeutics, to explore how innovative enzyme-based technologies are transforming drug discovery. Karsten shares the inspiration behind founding Sethera, the scientific challenges the company is addressing, and how its unique platform is enabling the discovery of next-generation peptide therapeutics for difficult-to-treat diseases.We discuss the power of enzymes in drug discovery, the promise of enzymatically constrained peptides, the role of AI and data in modern biotechnology, and the future of peptide-based medicines.Key Topics Discussed:The inspiration behind founding Sethera TherapeuticsThe unmet needs in drug discovery that Sethera aims to addressAn overview of Sethera's technology platform and missionWhat differentiates Sethera from other biotech companiesUnderstanding enzyme-enabled drug discovery in simple termsWhy enzymes are powerful tools for creating novel medicinesThe science and potential of enzymatically constrained peptidesAddressing hard-to-treat diseases and previously undruggable targetsDiscovering therapies for previously inaccessible biological targetsHow Sethera identifies, screens, and optimizes new moleculesThe role of data, AI, and machine learning in drug discoveryChallenges and lessons learned while building a biotechnology companyBalancing scientific innovation with business growth and executionBuilding high-performing, multidisciplinary biotech teamsEmerging trends shaping the future of biotechnology and drug discoveryThe future impact of peptide-based therapeutics on healthcareEpisode Highlights✔ The founding story behind Sethera Therapeutics✔ A simple explanation of enzyme-enabled drug discovery✔ Why constrained peptides represent an exciting new therapeutic class✔ How biotechnology is expanding the range of druggable targets✔ The growing role of AI, data, and advanced platforms in drug discovery✔ A vision for the future of precision medicine and patient careSubscribe to the Life Science Insights Podcast for more conversations with innovators and industry leaders shaping the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #SetheraTherapeutics #DrugDiscovery #Biotechnology #PeptideTherapeutics #Biotech #LifeSciences #PrecisionMedicine #DrugDevelopment #Enzymes #AIinBiotech #HealthcareInnovation #Biopharma #LifeSciencePodcast #futureofmedicine

In this episode of the Life Science Insights Podcast, we explore the future of MedTech collaboration, innovation, and community-driven growth with , Co-Founder of and White Lamb Medtech Consulting.In a conversation about her journey building platforms that connect MedTech professionals, strengthen industry partnerships, and support meaningful collaboration across the healthcare ecosystem. With over a decade of experience in global medical devices and regulatory strategy, she shares deep insights into navigating complex regulatory landscapes and scaling innovation across regions.

Key Topics DiscussedThe episode explores the founding vision behind indieMedTech and the industry gaps it aims to solve, along with the meaning of building a true “community” in MedTech. Holly discusses how regulatory expectations vary across global markets and how companies can successfully navigate these complexities.Additional themes include fostering authentic collaboration in a competitive industry, building successful MedTech partnerships, and avoiding common mistakes when scaling globally.

The conversation also highlights barriers to cross-stakeholder collaboration and how ecosystem alignment can accelerate innovation.Episode HighlightsThe inspiration and purpose behind founding indieMedTechThe evolving definition of community in MedTechStrategies for global regulatory navigationBuilding trust and collaboration in a competitive ecosystemCommon scaling mistakes in MedTech companiesSkills required for the next generation of MedTech professionalsHow professionals can build visibility and credibilityThe role of digital transformation in enabling innovationLeadership lessons from building a global MedTech networkMeasuring success through both growth and community impact.

The future of inclusive leadership in MedTechThe next 5–10 year outlook for MedTech ecosystemsAdvice for global expansion and cross-border innovationThe core message on collaboration driving MedTech progressThe episode closes with a reflection on the future of MedTech communities and how collaboration, shared learning, and ecosystem thinking will shape the next wave of healthcare innovation.

In this episode, we sit down with Levi S. Lian, CEO and Founder of Raycaster, to explore the critical evolution of document intelligence within the enterprise landscape. Drawing from a background that spans Stanford, Harvard Business School, and a deep-rooted family history in medicine, Levi shares his unique perspective on building AI-driven infrastructure that tackles one of the most persistent bottlenecks in modern business: the unstructured and complex document.

The conversation centers on the shift from traditional OCR and simple automation toward true document reasoning. We examine why scientific and technical documents pose such a significant challenge for legacy systems and how Raycaster is enabling organizations to move beyond mere data extraction to achieve actionable insights. We take a closer look at the strategic hurdles of enterprise AI adoption, discussing the vital balance between rapid product innovation and the rigorous demands of data security, accuracy, and regulatory compliance.

Listeners will gain a masterclass in the future of knowledge work and the ROI of modernizing document-heavy workflows. We discuss Levi’s journey as both a technical founder and an angel investor, offering insights into scaling AI infrastructure, overcoming misconceptions about machine intelligence, and the long-term risks facing industries that remain tethered to manual document processing.

In this episode, we are joined by Dr. Stanley T. Lewis, MD, MPH, Founder and CEO of A28 Therapeutics, to trace his profound transition from physician-scientist to biotech entrepreneur. With a career rooted in translational medicine and clinical development, Dr. Lewis provides an expert perspective on the arduous journey of moving innovation from the laboratory bench to the patient’s bedside. We dive into his mission to redefine precision oncology through Targeted Oncolytic Peptides (TOPs)—a novel modality designed to treat cancer with surgical precision while prioritizing the patient’s quality of life.

The conversation explores the strategic and scientific architecture required to build a therapeutics platform from scratch. We examine the lessons learned from Dr. Lewis’s previous success in bringing Trogarzo to market and how those cross-disciplinary insights from virology and infectious diseases are now being applied to solve unmet clinical needs in oncology. We take a closer look at the evolution of A28’s pipeline, discussing how the integration of biomarkers and advanced delivery systems is shaping the next generation of targeted cancer treatments.

Listeners will gain a rare look at the human-centered side of biotech leadership. We discuss the complexities of navigating regulatory milestones and financing, the importance of maintaining scientific rigor under the pressure of patient urgency, and why empathy remains the most critical component of medical innovation. Whether you are a scientist, a founder, or a healthcare leader, this episode offers a roadmap for balancing high-stakes operational execution with a steadfast focus on the human impact of medicine.

In this episode, we sit down with Ganesh Iyer, CEO and Founder of Opprtna Therapeutics and Drug Discovery Partners, to explore the high-stakes world of deep science entrepreneurship. Ganesh shares the personal and professional motivations that led him to tackle some of medicine's most formidable challenges—neurodegeneration and cancer. We delve into the founding vision of Opprtna and its pursuit of a "premium" therapeutics platform that leverages the unique capabilities of aptamers to reach targets once considered undruggable.

The conversation provides a technical yet accessible deep dive into aptamer-based modalities, comparing their precision and flexibility to traditional antibodies and small molecules. We examine the specific hurdles of Central Nervous System (CNS) targeting and the innovative delivery strategies required to cross the blood-brain barrier. Ganesh shares his expertise on translating early-stage preclinical discovery into clinical-ready assets, emphasizing the necessity of scientific rigor and strategic target selection in a competitive biotech landscape.

Listeners will gain a comprehensive look at the business of drug discovery, from navigating complex funding environments to building multidisciplinary teams that can scale. We discuss the balance between maintaining robust in-house capabilities and leveraging external partnerships to accelerate innovation. Whether you are an aspiring scientist-founder or a seasoned industry leader, this episode offers vital insights into the leadership, culture, and breakthroughs defining the next frontier of precision medicine.

In this episode, we sit down with Jodi Barrientos, CEO of Ribbon Bio, to explore how innovation infrastructure is shaping the future of synthetic biology—and why scalable DNA manufacturing is critical to unlocking the next generation of biological breakthroughs.

Jodi shares her journey from bench scientist to biotech entrepreneur, reflecting on the pivotal moments that inspired her to build a deep-tech company at the intersection of science, engineering, and advanced manufacturing. She discusses the founding vision behind Ribbon Bio and the mission to overcome longstanding limitations in traditional DNA synthesis technologies.

At the core of the conversation is the challenge of engineering long, complex, high-fidelity DNA constructs—an essential capability for advancing therapeutics, vaccines, agriculture, and industrial biotechnology. Jodi explains how integrating automation, precision engineering, and computational tools enables a new level of scalability and reliability in synthetic DNA production. By combining advanced manufacturing principles with biological design, Ribbon Bio is building the infrastructure needed to accelerate innovation across the life sciences ecosystem.

We also examine the growing role of computational tools and AI in DNA design—how digital modeling and predictive systems can optimize sequence construction, reduce errors, and streamline development cycles. Jodi highlights the commercialization challenges inherent in deep-tech biotech, from capital intensity to long development timelines, and shares leadership lessons learned while building resilient, highly technical teams.

Episode Highlights:
Ribbon Bio’s approach to redefining synthetic DNA manufacturing
Why scalable innovation infrastructure is critical for biotech growth
How precision, automation, and computational tools transform bioengineering
Insights into leading and scaling a deep-tech company
A forward-looking perspective on programmable biology and its impact across industries

This episode offers valuable insights for biotech founders, synthetic biology innovators, investors, and scientist-entrepreneurs seeking to understand how infrastructure, scale, and precision will define the future of programmable biology.

In this episode, we sit down with Jolly Nanda, Founder and CEO of Altheia, Inc., to explore how artificial intelligence is transforming precision medicine from a reactive model into one that is predictive, personalized, and proactive.

Jolly shares her entrepreneurial journey and the inspiration behind founding Altheia, highlighting the gaps she observed in traditional precision medicine approaches. While precision medicine has made meaningful progress, much of today’s healthcare system still reacts to disease after symptoms appear. Jolly explains how AI-driven insights are changing that paradigm—unlocking deeper understanding from complex patient data, accelerating diagnostics, and enabling earlier, more targeted interventions.

At the core of the conversation is the convergence of AI, clinical data, genomics, and digital health. By integrating multi-omics datasets with real-world clinical information, machine learning models can identify subtle patterns and correlations that would otherwise remain hidden. These insights allow for improved disease prediction, earlier detection, and more individualized therapeutic strategies tailored to each patient’s biological profile.

We also discuss the practical realities of building and scaling AI solutions in healthcare. From regulatory and interoperability challenges to adoption within clinical and commercial environments, Jolly outlines the importance of balancing innovation with trust, transparency, and governance. Responsible AI—grounded in ethical frameworks and robust validation—is essential to ensuring that predictive technologies truly serve patients and providers.

Episode Highlights:
How AI is shifting healthcare from reactive treatment to predictive, preventive care
The power of data-driven personalization in improving patient outcomes
Insights into building and scaling an AI-first precision medicine company
The importance of ethical frameworks, transparency, and responsible AI deployment
A forward-looking vision for AI-enabled, proactive healthcare innovation

This episode offers valuable perspective for healthcare leaders, digital health innovators, biopharma executives, and technologists seeking to understand how AI is reshaping precision medicine—and how predictive intelligence will define the next era of healthcare.

In this episode, we explore how San Diego is evolving as a global innovation hub—and what it will take to shape its next chapter at the convergence of AI, DefenseTech, and Life Sciences.

Long recognized for its strengths in biotech and research institutions, San Diego is now entering a new phase defined by cross-sector collaboration and technological convergence. We examine what differentiates the region from other emerging innovation hubs: a unique blend of research excellence, defense infrastructure, entrepreneurial culture, and global connectivity.

The conversation dives into how ecosystems can effectively support both early-stage startups and established industry leaders. As AI reshapes medtech, biotech, and adjacent sectors, the crossover between technology and life sciences is accelerating—unlocking new models of product development, commercialization, and impact. We discuss how founders can leverage this convergence to build more resilient and scalable companies.

We also address the realities entrepreneurs face today: evolving venture funding dynamics, heightened competition for capital, talent acquisition challenges, and the complexity of global expansion. Founders must move beyond pitching ideas to building investable, execution-ready organizations. Capital strategy now demands clarity, differentiation, and disciplined storytelling that resonates with both investors and customers.

A key theme of the episode is “StoryMaking”—the idea that momentum-driven narratives are more powerful than static origin stories. Translating deep science and complex technology into compelling, forward-looking messages is essential for attracting capital, talent, and partnerships. In a crowded global market, narrative clarity can be as important as technical excellence.

We also reflect on leadership within historic organizations navigating reinvention—how to balance legacy and culture with transformation and growth. Mentorship, long-term perspective, and principled decision-making play critical roles in shaping sustainable innovation ecosystems.

Episode Highlights:
A strategic look at San Diego’s next phase as a global innovation hub
Insights into the convergence of AI, DefenseTech, and Life Sciences
Practical guidance on capital strategy and investor readiness
A fresh perspective on StoryMaking as a driver of ecosystem momentum
Actionable advice for global scaling while maintaining focus and resilience
Leadership reflections on legacy, reinvention, and mentorship
Bold predictions on the future of global innovation ecosystems

This episode is essential listening for founders, investors, operators, and ecosystem builders working to shape not only San Diego’s future—but the broader trajectory of global innovation in the decade ahead.

In this episode, we sit down with Suzanne Vyvoda, Founder and CEO of Concordia BioStrategies, to explore how strategic leadership, operational rigor, and collaborative execution form the foundation of successful biotech companies.

Suzanne shares her journey to becoming a founder, CEO, and trusted strategic partner to emerging biotech organizations. She reflects on the philosophy behind Concordia BioStrategies—rooted in alignment, collaboration, and shared purpose—and why early-stage companies must build strong operational frameworks long before a clinical trial begins.

A central theme of the conversation is the evolving role of the Fractional C-Suite leader. Suzanne explains how this model provides growing biotechs with access to senior-level expertise without the overhead of full-time executive hires. In capital-constrained environments, fractional leadership allows companies to move strategically and efficiently—bringing experienced guidance during critical inflection points while preserving runway.

We dive into why operational excellence must start at the earliest stages of company formation. Too often, companies focus heavily on scientific progress while underestimating the infrastructure required to transition into clinical development. Suzanne outlines common operational pitfalls—from misaligned vendors and unclear governance structures to gaps in quality and compliance—and shares practical frameworks for aligning strategy, operations, and execution.

The conversation also emphasizes balance: how companies can move quickly without sacrificing quality, regulatory discipline, or scientific integrity. Early operational decisions, Suzanne notes, directly influence scalability, investor confidence, and ultimately patient impact. Creating alignment between founders, internal teams, CROs, and external partners is not optional—it is essential.

Episode Highlights:
A founder story grounded in collaboration, clarity, and execution
A clear explanation of the Fractional C-Suite model and its strategic value
Practical guidance on operational readiness before entering the clinic
Real-world insights into avoiding costly clinical-stage missteps
A thoughtful framework for balancing speed, quality, and long-term value creation

This episode is essential listening for biotech founders, emerging executives, and investors seeking to understand how disciplined operations, strategic alignment, and experienced leadership can accelerate the journey from discovery to the clinic—while building resilient companies designed for sustainable growth.

Join us for a powerful and timely episode featuring Golda Naana Boakye, CEO of Naantu, as we examine the urgent need to advance diversity, equity, and inclusion in clinical research. In this compelling conversation, Golda shares why representative clinical trials are not only a matter of social responsibility, but a scientific and clinical imperative essential to improving outcomes for all patients.

We explore the systemic and structural barriers that continue to limit participation from underrepresented communities, from historical mistrust and access challenges to trial design limitations that fail to reflect real-world populations. Golda discusses the importance of rebuilding trust through transparency, meaningful community engagement, and culturally competent communication—shifting clinical research from a transactional model to a patient-centered partnership.

The conversation also highlights how innovative, technology-enabled approaches are helping to remove logistical barriers, expand access, and enhance the participant experience. From decentralized trial models to data-driven outreach strategies, we examine how sponsors and CROs can move beyond intention and toward measurable action in equity-driven research.

Episode Highlights:
A deep dive into why diversity in clinical trials strengthens scientific validity and patient outcomes
Key structural barriers preventing broader participation—and how to address them
The critical role of trust, transparency, and community engagement in recruitment
How digital tools and decentralized models can improve accessibility and inclusivity
Golda’s leadership journey and the mission driving Naantu
Practical strategies for sponsors and research organizations to build more representative trials
A forward-looking vision for patient-centric, equitable clinical research

Whether you're a biopharma executive, clinical researcher, sponsor, or healthcare innovator, this episode offers strategic clarity and actionable insights on building trials that truly reflect the populations they aim to serve. Discover how inclusive research design is shaping the future of medicine—and why equity must be embedded at the core of scientific progress.

Join us for a strategic and deeply insightful episode featuring Ramani Varanasi, Founder and CEO of ReVive Advisors, as we explore the leadership mindset, capital strategy, and decision-making discipline required to build and scale successful biopharma companies. Drawing from his journey from bench scientist to executive leader, entrepreneur, and trusted board advisor, Ramani shares practical lessons shaped by decades of navigating high-stakes environments in biotech.

In this conversation, Ramani reflects on the pivotal moments that shaped his transition into leadership and company-building, offering candid perspectives on balancing bold scientific vision with operational pragmatism. We examine how strong leaders make informed decisions amid uncertainty—particularly during critical clinical, regulatory, and financial inflection points where data may be incomplete and timelines unforgiving.

The discussion dives into patterns Ramani has observed across high-performing biopharma organizations, from aligning scientific ambition with investor expectations to building leadership teams capable of disciplined execution. He shares frameworks for evaluating risk, structuring capital strategy, and making difficult calls when the stakes are high and resources constrained.

We also look ahead to the innovations reshaping the industry—AI, cell and gene therapy, and precision medicine—and explore how these technologies will influence strategy, capital allocation, and patient outcomes over the next decade.

Episode Highlights:
A candid leadership journey from bench science to boardroom influence
Practical insights on fundraising, capital strategy, and company scaling
Clear frameworks for navigating clinical and financial uncertainty
What distinguishes high-performing biotech founders and executive teams
A forward-looking perspective on AI and next-generation biopharma innovation

Whether you're a founder, executive, investor, or aspiring biotech leader, this episode offers strategic clarity and actionable guidance for building resilient organizations in a high-risk, high-reward industry. Discover how disciplined leadership, thoughtful capital strategy, and scientific vision come together to shape the future of biopharma.